Posted by Michael Wonder on 05 Dec 2023
ICER releases draft evidence report on treatment for paroxysmal nocturnal haemoglobinuria
5 December 2023 - Public comment period now open until 9 January 2024; requests to make oral comment during public meeting also being accepted.
The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of iptacopan (Novartis) and danicopan (Alexion Pharmaceuticals) for the treatment of paroxysmal nocturnal haemoglobinuria.
